



## Announcement Summary

**Entity name**

AMPLIA THERAPEUTICS LIMITED

**Announcement Type**

New announcement

**Date of this announcement**

23/7/2025

**The Proposed issue is:**

An offer of securities under a securities purchase plan  
A placement or other type of issue

**Total number of +securities proposed to be issued for an offer of securities under a securities purchase plan**

ASX +security code	+Security description	Maximum Number of +securities to be issued
ATX	ORDINARY FULLY PAID	10,869,566

**+Record date**

22/7/2025

**Offer closing date**

22/8/2025

**+Issue date**

29/8/2025

**Total number of +securities proposed to be issued for a placement or other type of issue**

ASX +security code	+Security description	Maximum Number of +securities to be issued
ATX	ORDINARY FULLY PAID	96,804,354

**Proposed +issue date**

29/7/2025

Refer to next page for full details of the announcement



---

**Part 1 - Entity and announcement details**

---

**1.1 Name of +Entity**

AMPLIA THERAPEUTICS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

**1.2 Registered Number Type**

ABN

**Registration Number**

16165160841

**1.3 ASX issuer code**

ATX

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

23/7/2025

**1.6 The Proposed issue is:**

An offer of +securities under a +securities purchase plan

A placement or other type of issue



Part 4 - Details of proposed offer under securities purchase plan

Part 4A - Conditions

**4A.1 Do any external approvals need to be obtained or other conditions satisfied before the offer of +securities under the +securities purchase plan issue can proceed on an unconditional basis?**

Yes

4A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
+Security holder approval	27/8/2025	Actual	

**Comments**

SPP subject to shareholder approval for the purposes of ASX Listing Rule 7.1, to be considered at Company's Annual General Meeting to be held on Wednesday 27 August 2025.

For personal use only



Part 4B - Offer details

**+Class or classes of +securities that will participate in the proposed issue and +class or classes of +securities proposed to be issued**

**ASX +security code and description**

ATX : ORDINARY FULLY PAID

**Will the proposed issue of this +security include an offer of attaching +securities?**

No

Details of +securities proposed to be issued

**ASX +security code and description**

ATX : ORDINARY FULLY PAID

**Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted**

10,869,566

**Will the offer be conditional on applications for a minimum number of +securities being received or a minimum amount being raised (i.e. a minimum subscription condition)?**

No

**Will the offer be conditional on applications for a maximum number of +securities being received or a maximum amount being raised (i.e. a maximum subscription condition)?**

No

**Will individual security holders be required to accept the offer for a minimum number or value of +securities (i.e. a minimum acceptance condition)?**

Yes

**Is the minimum acceptance unit based or dollar based?**

Dollar based (\$)

**Please enter the minimum acceptance value**

\$ 1,000

**Will individual security holders be limited to accepting the offer for a maximum number or value of +securities (i.e. a maximum acceptance condition)?**

Yes

**Is the maximum acceptance unit based or dollar based?**

Dollar based (\$)

**Please enter the maximum acceptance value**

\$ 100,000



**Describe all the applicable parcels available for this offer in number of securities or dollar value**

\$1,000 \$2,500 \$5,000 \$10,000 \$15,000 \$20,000 \$30,000 \$40,000 \$50,000 \$60,000 \$70,000  
\$80,000 \$90,000 \$100,000

**Offer price details**

**Has the offer price been determined?**

No

**In what currency will the offer be made?**

AUD - Australian Dollar

**How and when will the offer price be determined?**

The lower of:  
- \$0.23; and  
- a 5.0% discount to the VWAP of ATX shares over the last five trading days of the SPP offer period, rounded to the nearest half-cent.

**Oversubscription & Scale back details**

**Will a scale back be applied if the offer is over-subscribed?**

Yes

**Describe the scale back arrangements**

The Company may, in its absolute discretion, undertake a scale-back. In doing so, the Company may have regard to shareholdings of eligible shareholders as at the SPP record date who applied for SPP Shares such that participating shareholders would receive an amount of SPP Shares that at least maintains their percentage shareholding in the Company (or a lesser number, if applied for), subject to the maximum application size of \$100,000.

**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes

Part 4C - Timetable

**4C.1 Date of announcement of +security purchase plan**

23/7/2025

**4C.2 +Record date**

22/7/2025

**4C.3 Date on which offer documents will be made available to investors**

1/8/2025

**4C.4 Offer open date**

1/8/2025

**4C.5 Offer closing date**

22/8/2025

**4C.7 +Issue date and last day for entity to announce results of +security**



**purchase plan offer**

29/8/2025

Part 4D - Listing Rule requirements

**4D.1 Does the offer under the +securities purchase plan meet all of the requirements of listing rule 7.2 exception 5 or do you have a waiver from those requirements?**

No

**4D.1a Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

No

**4D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?**

No

Part 4E - Fees and expenses

**4E.1 Will there be a lead manager or broker to the proposed offer?**

Yes

**4E.1a Who is the lead manager/broker?**

Bell Potter Securities Limited

**4E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?**

5.5%

**4E.2 Is the proposed offer to be underwritten?**

No

**4E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?**

No

**4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer**

Legal Fees \$25k  
Share Registry Fees \$25k  
Shareholder Engagement \$10k

Part 4F - Further Information

**4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue**

Completion of the ACCENT TRIAL, initiation of a Phase 2b/3 trial, Amplicity Trial in the US with narmafotonib in conjunction with FOLFIRINOX, preliminary KRAS and/or Ovarian trial/studies, drug manufacturing, operations, working capital and offer costs

**4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful?**

No

**4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer**

Canada, Hong Kong, Liechtenstein, Singapore, Spain, Swaziland, Switzerland, Thailand, United Kingdom, United States of America



**4F.3 URL on the entity's website where investors can download information about the proposed offer**

<https://ampliatx.com/announcements>

**4F.4 Any other information the entity wishes to provide about the proposed offer**

The Company is seeking to raise \$2,500,000 under the SPP, however retains the discretion to raise up to an additional \$7,500,000 (for a total of up to \$10,000,000). The maximum number of shares to be issued under the SPP depends on the maximum dollar value that may be raised up to \$10,000,000, if the Company elects to accept over-subscriptions and the SPP Offer Price. If \$10,000,000 is raised and the SPP Offer Price is \$0.23 then the number of shares to be issued under the SPP will be 43,478,261 (subject to rounding). If the SPP Offer Price is lower than \$0.23 then the maximum number of shares that may be issued under the SPP will increase.

For personal use only



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

**7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?**

No

Part 7B - Issue details

**Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?**

Existing class

**Will the proposed issue of this +security include an offer of attaching +securities?**

No

Details of +securities proposed to be issued

**ASX +security code and description**

ATX : ORDINARY FULLY PAID

**Number of +securities proposed to be issued**

96,804,354

**Offer price details**

**Are the +securities proposed to be issued being issued for a cash consideration?**

Yes

**In what currency is the cash consideration being paid?**

AUD - Australian Dollar

**What is the issue price per +security?**

AUD 0.23000

**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes



Part 7C - Timetable

---

**7C.1 Proposed +issue date**

29/7/2025

Part 7D - Listing Rule requirements

---

**7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?**  
No

**7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

Yes

**7D.1b ( i ) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

57,937,087

**7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?**

Yes

**7D.1c ( i ) How many +securities are proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A?**

38,867,267

**7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?**

No

**7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?**

No

**7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?**

No

Part 7E - Fees and expenses

---

**7E.1 Will there be a lead manager or broker to the proposed issue?**

Yes

**7E.1a Who is the lead manager/broker?**

Bell Potter Securities Limited

**7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?**

5.5%

**7E.2 Is the proposed issue to be underwritten?**

No

**7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue**

Legal \$45k  
Share Registry \$10k



Part 7F - Further Information

---

**7F.01 The purpose(s) for which the entity is issuing the securities**

Completion of the ACCENT TRIAL, initiation of a Phase 2b/3 trial, Amplicity Trial in the US with narmafotonib in conjunction with FOLFIRINOX, preliminary KRAS and/or Ovarian trial/studies, drug manufacturing, operations, working capital and offer costs.

**7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?**

No

**7F.2 Any other information the entity wishes to provide about the proposed issue**

The Placement is being undertaken in conjunction with a Share Purchase Plan, Conditional Placement and Director Placement to raise gross proceeds of \$27.5 million. The Conditional Placement, Director Placement and Share Purchase Plan are conditional on shareholder approval and will be considered at the Company's Annual General Meeting to be held on 27 August 2025.

**7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:**

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)